pf-07799544 + encorafenib

PF-07799544 + encorafenib is an investigational combination regimen of a next-generation, brain-penetrant MEK inhibitor (PF-07799544) and a BRAF inhibitor (encorafenib, marketed as BRAFTOVI) administered orally. PF-07799544 inhibits MEK, a key kinase in the MAPK signaling pathway implicated in tumor growth and progression, while encorafenib inhibits mutant BRAF kinase, targeting tumors harboring BRAF mutations. The combination is being studied in advanced solid tumors, particularly BRAF-mutant melanoma and other solid tumors with BRAF alterations, with the aim to suppress MAPK pathway signaling more effectively than either drug alone[1][3][4][5][7]. PF-07799544 is currently investigational and not FDA approved, while encorafenib is approved for certain cancer indications.

Brand names

BRAFTOVI

Other names

encorafenibBRAFTOVI